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Introduction
HSV1716 is a selectively replication-competent mutant of herpes simplex virus type 1 lacking both copies of the gene encoding the virulence factor ICP34.5.
1,2 Replication of HSV1716 is cell type-and state-dependent. Specifically it replicates in actively dividing but not in terminally differentiated cells. 3 The virus lyses human glioblastoma cells in vitro 4 and in model systems, it eliminates brain tumours whilst failing to replicate in normal tissue. [5] [6] [7] [8] We previously demonstrated the safety of intratumoural administration of HSV1716 up to doses of 10 5 p.f.u. in patients with recurrent high-grade glioma (HGG). 9 In addition, in patients with metastatic melanoma, HSV1716 has been shown to be nontoxic, as well as selectively replicating in melanoma cells. 10 The safety of oncolytic HSV has also been demonstrated in patients with HGG using 
patients, HSV1716, in excess of the input dose was recovered from the injection site. HSV DNA was detected by PCR at the sites of inoculation in 10 patients and at distal tumour sites in four. HSV-specific antigen was detected in tumour tissue from two patients. In five patients an immunological response to HSV1716, as detected by changes in levels of IgG and IgM, was demonstrated. This study demonstrates that HSV1716 replicates in HGG without causing toxicity in both HSV-seropositive and -seronegative patients.
Gene Therapy (2002) 9, 398-406. DOI: 10.1038/sj/gt/3301664 a virus with an ICP34.5 null mutation plus a mutation in ribonucleotide reductase. 11 We believe that for a replication-competent virus, doselimiting toxicity studies may not be appropriate and that novel biological agents, which depart from traditional radio-and chemotherapeutic modalities for cancer, require a re-evaluation of development strategy. The rationale for this is two-fold: (1) The intrinsic replication capacity of HSV1716 means that the input dose is likely to escalate within the tumour and thus may be largely irrelevant and (2) HSV1716 is a deletion mutant in which the gene conferring virulence has been removed thus, irrespective of dose, the virus is effectively nontoxic in non-replicating cells. Hence the dose needed for efficacy should be dissociated from any dose likely to produce toxicity. In model systems two p.f.u. of wild-type HSV1 cause fatal encephalitis whereas >10 6 p.f.u. of HSV1716 are avirulent when injected into the brain. 2 In this study, using a single dose of HSV1716, we establish a 'proof of principle' by demonstrating that the virus replicates in human HGG following intratumoural injection.
Results

Clinical details
Twelve patients were included in this study: five females and seven males; age range 38 to 64 years, Karnofsky scores between 60 and 90 and Barthel indices ranging from 16 to 21. Eleven patients had recurrent tumours and one was newly diagnosed. The recurrent tumours included six with recurrence of a previous glioblastoma multiforme (in three, this was the second recurrence) and five with a higher-grade transformation of a previously low-grade glioma. Their clinical profiles are given in Table 1 .
Patients considered for the study underwent a comprehensive work-up, including general clinical and neurological evaluation. Imaging modalities included CT scanning, Gadolinium-enhanced MRI and thallium and HMPOA SPECT scans. Clinical parameters were identified immediately before inoculation and all pathology was reported after contemporary review by a neuropathologist.
Up to 1 week before virus inoculation, immunological, haematological and biochemical tests were carried out as in our previous study. 9 Immunological tests were not repeated post-operatively. The results (data not shown) demonstrated a significant degree of impaired immunocompetence similar to that reported by Rampling et al, 9 as expected in this group of patients.
Each patient received an intratumoural dose of 10 5 p.f.u. of HSV1716 in 1 ml by stereotactic injection and resection was carried out between 4 and 9 days later. No patient experienced adverse symptoms from the HSV1716 injection. Their clinical course post-tumour resection was standard for this group of patients. One patient (patient 8) suffered an intracerebral haemorrhage the day after his second operation, having recovered from the procedure without deficits. The clot was evacuated urgently, but his neurological condition failed to improve significantly and he died 2 months later. One other patient (patient 12) did not improve sufficiently after tumour resection to receive further treatment and he died a month later. Nine patients received radiotherapy or chemotherapy after surgery. Six patients have died at the time of reporting. The median survival from study inclusion is greater than 7 months. The clinical details at 3 months post-injection and in April 2001 are summarised in Table 2 .
Analyses of tumour tissue and serum samples
The following assays were performed: infectious virus determined by plaque assay; Southern blot analysis of DNA from virus recovered from biopsy samples; PCR analysis for HSV DNA; immunohistochemistry for HSV antigens; Elisa assays for HSV specific IgG and IgM in sera.
The results of the analyses are given in Table 3 and Figure 1 .
Recovery of HSV 1716:
In two patients (1 and 11), infectious virus was recovered from resected tumours ( Table  3) . In patient 1, virus was detected in three separate biopsy samples taken from the injection site. One of the samples which contained liquefied material, yielded 4 × 10 5 p.f.u., while the other two samples, each yielded 40 p.f.u. Virus was not detected in a fourth distal tumour Gene Therapy sample. In patient 11, virus (3 × 10 5 p.f.u.) was detected in the single biopsy from the injection site. Virus was not detected in the paired distal tumour sample. Southern blot analyses confirmed that the recovered virus was HSV1716 (data not shown).
PCR for HSV DNA: Semi-quantititative PCR for detection of HSV DNA was carried out in both blood and tumour samples. Apart from that of patient 9, no other blood sample showed evidence of HSV DNA. When resected tumour tissue was analysed, HSV DNA was detected at the injection site in 10 out of 12 patients. In the paired samples from the distal tumour sites, four out of 10 were positive for HSV DNA.
A post-mortem examination was carried out on patient 1 who died 251 days after HSV1716 injection. Brain tissue was obtained from the right and left temporal lobe, the occipital lobe, peri-tumour and tumour centre. One of the tumour centre samples was PCR positive for HSV DNA (5 × 10 3 genomes were detected by the semi-quantitative method).
Immunohistochemistry for HSV antigen: Tumour tissue was analysed by immunohistochemistry using two monoclonal antibodies to: (1) the UL42 protein; and (2) an unspecified epitope of HSV 1 strain Stoker. Specific antigen was detected by both antibodies in injection site tissue from two patients (4 and 11). Staining by monoclonal antibody of tumour from these patients is shown in Figure 2 .
HSV immune status:
Serum samples, taken pre-HSV1716 injection and at various times after injection, were assayed for both HSV-specific IgG and IgM ( Figure 1) . Two of the patients (1 and 11) were seronegative for HSV1 before injection. Both of these patients seroconverted with specific IgG and IgM responses several days after tumour resection. For patient 1, a specific immune response was first detected 13 days post resection (pr), ie 19 days after HSV1716 injection. The IgG reached a peak on the 83rd day, whereas the IgM peaked on the 53rd day pr. In patient 11, an increase in specific IgG was first detected 16 days pr, ie 21 days after injection. By 37 days pr, the IgM had substantially increased. Both IgG and IgM reached a peak on day 51 pr. In addition, three seropositive patients (5, 8 and 10) mounted an HSV1 IgM response after tumour resection. In patient 5, the response began on day 4 and peaked at day 31 pr; in patient 8, the response began on day 3 pr and continued to rise up to day 7 pr, after which it was not possible to obtain further samples. In patient 10, the IgM response was first detected 99 days pr and peaked at day 113 pr. In the serum from patient 9, on the day following tumour resection, HSV DNA was detected by PCR. This cleared within 24 h. It should be noted that this patient's IgG and IgM levels remained relatively constant.
Discussion
The two toxicity studies using replication-competent HSV in glioma patients, which have been reported, did not allow assessment of virus replication.
9,11 Although we have obtained subsequent evidence of HSV1716 replication in melanoma tumours, 10 both the nature of the disease and the composition of the tissue (skin versus brain) GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; A, astrocytoma; NB, no biopsy; NA, not applicable; Rx, treatment; S, surgery; XRT, radiotherapy; Ch, chemotherapy; KS, Karnofsky score; Aml, amlodipine; Dhc, dihydrocodeine; Lan, lanzaprazole; Ran, ranitidine; B, bendrofluazide; Fus, fusinopril; Los, losec; Tri, tridastra; Cbz, carbamazepine; Gab, gabapentin; Nyz, nyzaditine; Trim, trimethoprim; Dex, dexamethasone; Lam, lamotrigine; P, paracetamol; Val, valproate. Evidence of HSV1716 replication in HGG has been obtained from a number of assays. Significantly, in two patients, infectious virus was recovered from tissue at the injection sites, but not from distal tumour sites. The amount of virus recovered was more than the input dose and was present in a minute amount of tissue. Given the constraints in sampling, it is highly encouraging that infectious virus could be recovered.
The two patients from whom virus was recovered were both HSV seronegative at the time of injection and both subsequently seroconverted. This could be interpreted to mean that HSV1716 will only replicate in seronegative patients and in seropositive individuals, virus will be cleared rapidly and replication limited. This would imply a degree of immune surveillance in the brain. However, a number of issues have to be taken into consideration. We have evidence from semi-quantitative PCR that in seropositive individuals (patients 4 and 5, Table 3 ), Gene Therapy HSV1716 replicated to substantial levels. It should also be noted from the PCR analyses of samples from patients 1 and 11, that there was no HSV DNA found at distal tumour sites, whereas in seropositive patients (2, 3, 5 and 10) evidence of HSV DNA at distal tumour sites was obtained. In the immunohistochemistry assays, there is also evidence of virus replication in patient 2 who was seropositive at the time of virus injection.
It should be borne in mind that HSV travels by cell to cell spread, as well as extracellularly. We know that HSV1716 can replicate in melanoma in seropositive individuals and a second injection of HSV1716 into the same nodule resulted in tumour flattening. 10 This is direct evidence that HSV antibody did not stop HSV1716 from replicating and killing tumour cells in the skin, which, unlike the brain, is a site where immune surveillance will readily take place. 12 Perhaps a more likely explanation for the failure to recover virus from seropositive patients is that, during tumour resection, there is inevitably contact between tissue and blood containing neutralising antibodies. Historically, human serum was used in HSV plaque assays to stop the spread of virus released from infected cells. 13 It is also documented that an individual's susceptibility to recurrent HSV infections (virus replication) cannot be correlated with quantitative or qualitative changes in the levels of virus specific antibodies. Until we have substantially increased numbers of both seropositive and seronegative patients, no definitive conclusions on the role of patient anti-HSV antibodies in controlling HSV1716 replication in tumours in vivo can be drawn.
HSV DNA was detected by PCR in tissue from the injection sites in 10 patients and from distal tumour sites in four of the 10. The assay does not distinguish between wild-type HSV and HSV1716, however Southern blot analysis on recovered infectious virus confirmed that it was HSV1716. In our opinion, it is highly unlikely that residual genomes could survive without replication for up to 9 days and still be detected by PCR assay. Additionally, in four cases, semi-quantitative PCR analyses detected HSV genomes at a level in excess of the amount inoculated. It should be taken into account that identification of the injection site is subject to the constraints of image-guided neurosurgery. Also, the sample analysed (a total volume of a few cubic millimetres in a total tumour volume of several cubic centimetres) is only a fraction of the tissue from the injection site. Given these considerations, the case for HSV1716 replication, as identified by semi-quantitative PCR, is very strong.
Immunohistochemical analyses have been complicated by cross-reaction of HSV antibodies with glioblastoma surface antigens.
14 Optimisation of the assay for HSV antigen using two monoclonal antibodies gave positive results in tumour tissue from two patients. The patients (4 and 11) were those in whom the semi-quantitative PCR showed the highest number of HSV genomes (1 × 10 6 p.f.u.). The UL42 gene encodes an early protein, the presence of which, 9 days after infection indicates de novo protein synthesis.
Analysis of serum samples demonstrated changes in the circulating levels of HSV-specific IgG and IgM in five patients. Two seronegative patients, seroconverted and three other patients (5, 8 and 10) showed an IgM response post resection, indicating that viral antigen entered the systemic circulation. In patient 10, surprisingly this response first occurred at 99 days after resection and may indicate that there was a burst of virus replication. Within 24 h of tumour resection, patient 9 had a positive blood PCR result for HSV DNA, which was rapidly cleared without intervention and with no apparent change in immunoglobulin levels. The timing suggests that HSV1716 entered the systemic circulation during tumour resection. Of interest, the only HSV-seronegative patient in our previous study did not have an early resection after virus injection and failed to seroconvert.
We conclude that HSV1716 replicates in HGG in situ without causing toxicity. We have now commenced a study in which HSV1716 is being injected into brain adjacent to tumour following tumour resection. This study should provide additional safety data and should allow assessment of efficacy.
Patients and methods
Inclusion criteria
Patients were considered for inclusion into the study either at initial presentation with a suspected HGG, at recurrence of previously diagnosed HGG or at progression and suspected anaplastic transformation of previously diagnosed low-grade glioma. Only patients with supratentorial tumours in whom surgical resection was clinically indicated and whose clinical condition allowed initial biopsy and virus injection at least 7 days before resective surgery were offered entry. Patients had to be 18-70 years of age with a Karnofsky score у60. Patients with active acute infection, known HIV-positive or other severe systemic disease were excluded. Patients and their families were counselled on a number of occasions at least 24 h apart by the two principal investigators (VP and RR), as well as an independent clinician (RP), before obtaining their informed consent for participation into the study. The study protocol was approved by the local Ethics Committee, the Gene Therapy Advisory Committee for the UK and the Medicines Control Agency. 
Operative procedures
The first procedure was performed under general anaesthesia using the Leksell stereotactic frame. A stereotactic biopsy was obtained from the proposed injection site and following confirmation of the presence of viable tumour on a smear preparation, virus was administered. A total volume of 1 ml, containing 10 5 p.f.u. HSV1716, was injected in nine aliquots using a fine needle projecting through the standard side-ending biopsy needle. These were injected at three levels, 5 mm apart along the biopsy needle trajectory, with three 120°radial injections perpendicular to its long axis, at each level. An immediate CT scan was performed to identify the injection site and exclude any per-operative complications. Routine postoperative care was instigated including repeat imaging and blood investigations.
Four to 9 days later, the patient underwent imageguided craniotomy, using the BrainLab VectorVision system, for tumour resection under general anaesthesia. The immediate post-injection CT scan was fused with a CT scan on the day of surgery in order to assist with localisation of the injection site for biopsy purposes. Once the injection site was identified, several biopsy samples were taken, along with paired samples from distal areas of the tumour.
Virus production GMP-grade HSV1716 was manufactured by Q1 Biotech, Glasgow, UK. A paired sample of virus was titrated previrus administration to the patients. Details have been described by Rampling et al. 9 Tissue and blood assays Immunological investigations and lymphocyte functions assays were carried out as described by Rampling et al. 9 Assay for infectious HSV was carried out by homogenising tissue samples, sonicating the cells, centrifuging to remove debris and adding the supernatant to monolayers of BHK21/C13 cells which were then examined over 7 days for evidence of cytopathic effect and/or HSV plaques. Serum samples were assayed similarly.
Southern blot analysis of recovered virus
Single plaque isolates were used to infect BHK monolayers in Linbro wells. After 24 h, DNA was extracted from the wells by cell lysis followed by phenol/chloroform extraction and ethanol precipitation. The DNA was digested with BamHI and run on an agarose gel alongside similarly digested controls of HSV1716 and wild-type HSV1 strain 17 + DNA. The gel was Southern blotted on to a nylon membrane and UV cross-linked. The membrane was probed with 32 P-labelled BamHI k(v+s) and used for autoradiography. HSV1716 DNA is distinguishable from wild-type HSV DNA by a reduction in size of the BamHIs fragment.
ELISA for HSV-1 IgG and IgM was carried out using a Virotech (Russelsheim, Germany) HSV-1-specific kit as described by Rampling et al. 9 PCR assays DNA was extracted from biopsy samples using a Nucleon Biosciences (Coatbridge, UK) ST (soft tissue) Genomic DNA Extraction Kit. The DNA pellet was resuspended in TE buffer and the concentration measured by agarose gel electrophoresis and spectrophotometry before being used for the PCR assay. DNA extracted from BHK cells infected with HSV1716 was used as controls. The primers chosen were HS13 (ACG ACG ACG TCC GAC GGC GA) and HS14 (GTG CTG GTG CTG GAC GAC AC). These detect UL42 locus of HSV 15 and are made-up as 1 nM/l stocks in sterile, de-ionised water. PCR reagents used per reaction were: 1.5 l 10 mM dNTPs; 5 l Pfx amplification buffer; 0.5 l platinum Pfx DNA polymerase (Gibco BRL, Paisley, UK); 1 l 50 mM Mg 2 SO 4 ; 1 l 0.1 nM dilution of HS13; 1 l 10-fold Gene Therapy dilution of HS14; 1 l DNA template; made up to 50 l total volume in sterile, de-ionised water. PCR conditions were 94°C for 2 min; 32 cycles × (94°C for 15 s; 72°C for 1 min; 72°C for 1 min); 72°C for 1 min; soak at 4°C.
Semi-quantitative PCR assay was performed to indicate the number of viral genome copies present in the samples assayed. These results were normalised to the volume in which the extracted DNA was resuspended for the assay. The level of sensitivity was 1 × 10 2 HSV genomes per tissue sample as estimated from reconstruction experiments using DNA from infected BHK cells. After PCR, 20 l of each reaction was run on a 1% agarose gel and observed for a 278-bp band indicative of HSV.
Immunohistochemistry
Immunohistochemistry for HSV was performed on paraffin sections using monoclonal antibodies recognising the HSV1 UL 42 protein (Z1F11, a gift from Howard Marsden, MRC Virology Unit, Glasgow, UK) and an unspecified epitope of HSV1 strain Stoker (DAKO). Sections were pretreated by microwaving for antigen retrieval. Bound antibody was visualised using a multilink kit (Menarini) and diaminobenzidine. Sections from wild-type HSV1 encephalitis were used as positive controls. Negative controls were HGG tumours that had not received HSV1716.
